CBL mutation in childhood therapy-related leukemia

Leukemia

Volumn 25, Issue 8, 2011, Pages 1356-1358

  Shiba, N ^a,b   Taki, T ^c   Park, M J ^a   Nagasawa, M ^d   Kanazawa, T ^b   Takita, J ^e   Ohnishi, H ^f   Sotomatsu, M ^a   Arakawa, H ^b   Hayashi, Y ^a  

^a Gunma Children's Medical Center   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CBL PROTEIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; K RAS PROTEIN; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; PROTEIN TYROSINE KINASE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; BLAST CELL; BONE MARROW BIOPSY; BONE MARROW CELL; BUCCAL LYMPH NODE BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER THERAPY; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; ENZYME ACTIVATION; EXON; FEMALE; GENE REARRANGEMENT; GENETIC ANALYSIS; HOMOZYGOSITY; HUMAN; IN SITU HYBRIDIZATION; JUVENILE MYELOMONOCYTIC LEUKEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LETTER; LEUKEMOGENESIS; LEUKOCYTOSIS; LYMPH NODE BIOPSY; LYMPHOMA; MALE; MULTIMODALITY CANCER THERAPY; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; ONCOGENE K RAS; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SOUTHERN BLOTTING; SPLENECTOMY; SPLENOMEGALY; TUMOR CELL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENE PROTEINS C-CBL; TRANSLOCATION, GENETIC;

EID: 80051788548     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.75     Document Type: Letter

References (8)

1. Tucker MA, Meadows AT, Boice Jr JD, Stovall M, Oberlin O, Stone BJ et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-464. (Pubitemid 17036759)
2. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC et al. Acute myeloid leukemias in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-1687.
3. Nakada S, Katsuki Y, Imoto I, Yokoyama T, Nagasawa M, Inazawa J et al. Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J Clin Invest 2006;116:80-89. (Pubitemid 43121793)
4. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-6192.
5. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009;460:904-908.
6. Shiba N, Kato M, Park MJ, Sanada M, Ito E, Fukushima K et al. CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome. Leukemia 2010;24:1090-1092.
7. Sugita K, Furukawa T, Tsuchida M, Okawa Y, Nakazawa S, Akatsuka J et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 1993;15:99-104. (Pubitemid 23061717)
8. Fu JF, Hsu JJ, Tang TC, Shih LY. Identification of CBL, a protooncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes Cancer 2003;37:214-219.